Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

NCT05134649 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05134649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05134649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2021
Completion date
August 18, 2023
Enrollment
292 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

platysma prominence